SEC Form 4 · accession 0001104659-26-108247
Cytosorbents Corp · CTSO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent Capponi
Officer — President and COO
Period of report
Sep 14, 2026
Accepted (ET)
Sep 16, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001175151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F4,F5 | Sep 14, 2026 | P | 1,800 | $6.07 | A | 40,114 | D | |
| Common StockF1,F2,F3,F4,F5 | Sep 14, 2026 | P | 273 | $5.90 | A | 40,387 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.
- F2Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015;
- F3(continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and
- F4(continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person.
- F5Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.